New anxiety drug shows promise in early brain study
NCT ID NCT07478744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single dose of the experimental drug SYT-510 can reduce anxiety-related brain activity and behavior in 24 adults with generalized anxiety disorder. Participants will receive either the drug or a placebo, then switch after a washout period. The goal is to see if SYT-510 affects brain scans and defensive responses, helping design future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SLaM
RECRUITINGLondon, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill quiet the mind? a large trial puts it to the test
- Can a unified therapy tame both addiction and emotional disorders?
- Can learning Self-Compassion quiet anxiety and depression?
- A common antidepressant may tame anxiety in kids with autism and ADHD — a trial puts it to the test
- Can money worries trigger depression in students? a study digs deep
- Could a group therapy tackle both depression and anxiety in teens?